Article
Impact of Homologous Recombination Deficiency on Outcomes in Patients With Triple-Negative Breast Cancer Treated With Carboplatin-Based Neoadjuvant Chemotherapy: Secondary Analysis of the NeoCART Randomized Clinical Trial.
JCO precision oncology - 1 Jan 2023
Zhang Liulu, Wu Zhiyong, Li Jie, Zhu Dongqin, Yang Lingling, Shao Yang, Lin Ying, Liu Zhenzhen, Cao Yin, Zhang Gangling, Shang Shiyao, Zhang Yi, Wang Kun
Abstract excerpt
PURPOSE: Pathologic complete response (pCR) rates of patients with triple-negative breast cancer who were administered docetaxel plus carboplatin were significantly higher than those of patients administered epirubicin/cyclophosphamide followed by docetaxel in the neoadjuvant NeoCART trial. Here, we performed a preplanned secondary analysis of the homologous recombination deficiency (HRD) score as a predictor of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.